The difficulties of chronic disease can affect many areas of life — perhaps even mental health. I'm Miranda Savioli with your latest health news.
A new study found that people with a chronic disease, such as type 2 diabetes or asthma, had increased odds of also having psychiatric distress. These odds increased with every reported chronic disease. Women, smokers, binge drinkers, and obese patients were also more likely to suffer mental distress with a chronic disease.
Seek help if negative emotions are interfering with your everyday life.
As a family owned and operated business, at GoodPill, our passion is your wellbeing. Check out our new Online Store and have all those products shipped or delivered for FREE. Restrictions apply. GoodPill Pharmacy and Medical Supplies services and offer FREE delivery to Pembroke Pines, Miramar, Southwest Ranches, Weston, Cooper City, Davie, and Hollywood community in Florida. Zip codes include: 33025, 33026, 33027, 33028, 33029, 33330, 33331, 33332, 33325, 33326, & 33327. If you live outside this area, our products can be shipped to you. Call 754-201-3663 for more information.
Alam F, et al. – Diabetic wounds are unlike typical wounds in that they are slower to heal, making treatment with conventional topical medications an uphill process. The potential role of honey’s antibacterial activity on diabetic wound–related microorganisms and honey’s clinical effectiveness in treating diabetic wounds based on the most recent studies is described.
Additionally, ways in which honey can be used as a safer, faster, and effective healing agent for diabetic wounds in comparison with other synthetic medications in terms of microbial resistance and treatment costs are also described to support its traditional claims.
Taken from Evidence-based Complementary and Alternative Medicine
Past studies have suggested that low vitamin D may be tied to an increased risk for type 2 diabetes. But new research challenges that notion. I'm Erin White with your latest health news.
Type 2 diabetes is a condition in which the body becomes resistant to insulin. Researchers recently found that type 2 diabetes patients often had low levels of vitamin D, but these vitamin D levels did not appear to be the cause of the patients' diabetes.
Ask your doctor about how to best prevent type 2 diabetes.
Taken from DailyRx.
"Afrezza is a new treatment option for patients with diabetes requiring mealtime insulin," said Jean–Marc Guettier, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval broadens the options available for delivering mealtime insulin in the overall management of patients with diabetes who require it to control blood sugar levels.” The drug’s safety and effectiveness were evaluated in a total of 3,017 participants–1,026 participants with type 1 diabetes and 1,991 patients with type 2 diabetes. The efficacy of mealtime Afrezza in adult patients with type 1 diabetes patients was compared to mealtime insulin apart, both in combination with basal insulin in a 24 week study.
At week 24, treatment with basal insulin and mealtime Afrezza provided a mean reduction in HbA1c that met the pre–specified non–inferiority margin of 0.4 percent. Afrezza provided less HbA1c reduction than insulin aspart, and the difference was statistically significant. Afrezza was studied in adults with type 2 diabetes in combination with oral antidiabetic drugs; the efficacy of mealtime Afrezza in type 2 diabetes patients was compared to placebo inhalation in a 24 week study. At week 24, treatment with Afrezza plus oral antidiabetic drugs provided a mean reduction in HbA1c that was statistically significantly greater compared to the HbA1c reduction observed in the placebo group. Afrezza is not a substitute for long–acting insulin. Afrezza must be used in combination with long–acting insulin in patients with type 1 diabetes, and it is not recommended for the treatment of diabetic ketoacidosis, or in patients who smoke. Afrezza has a Boxed Warning advising that acute bronchospasm has been observed in patients with asthma and COPD.
Taken from FDA Press Announcements
Working overtime may result in a bigger paycheck, but it may also be linked with some serious health problems. I'm Erin White with your latest health news.
A recent review of past studies looked at the health effects of working overtime. The study authors found that low-income people doing manual work who had longer shifts were more likely to develop type 2 diabetes than people working 35 to 40 hours per week. Type 2 diabetes occurs when a patient becomes resistant to insulin, the hormone that regulates blood sugar and metabolism.
Taken from DailyRX.
The U.S. Food and Drug Administration approved Trulicity (dulaglutide), a once–weekly subcutaneous injection to improve glycemic control, along with diet and exercise, in adults with type 2 diabetes. Trulicity is a new treatment option, which can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of type 2 diabetes. Trulicity is a glucagon–like peptide–1 (GLP–1) receptor agonist.
The drug’s safety and effectiveness were evaluated in six clinical trials in which 3,342 patients with type 2 diabetes received Trulicity. Patients receiving Trulicity had an improvement in their blood sugar control as observed with reductions in HbA1c level. Trulicity has been studied as a stand–alone therapy and in combination with other type 2 diabetes therapies, including metformin, sulfonylurea, thiazolidinedione, and prandial insulin.
Trulicity should not be used to treat people with type 1 diabetes; those who have diabetic ketoacidosis; those with severe stomach or intestinal problems; or as first–line therapy for patients who cannot be managed with diet and exercise. Trulicity has a boxed warning that tumors of the thyroid gland (thyroid C–cell tumors) have been observed in rodent studies with Trulicity but that it is unknown whether Trulicity causes thyroid C–cell tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC), in humans. Trulicity should not be used in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2.
Taken from FDA Press Announcements
The U.S. Food and Drug Administration approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. "Jardiance provides an additional treatment option for the care of patients with type 2 diabetes," said Curtis J. Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes.”
Jardiance is a sodium glucose co–transporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose (blood sugar) by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levels. The drug’s safety and effectiveness were evaluated in seven clinical trials with 4,480 patients with type 2 diabetes receiving Jardiance. The pivotal trials showed that Jardiance improved hemoglobin A1c levels (a measure of blood sugar control) compared to placebo. Jardiance should not be used: to treat people with type 1 diabetes; in those who have increased ketones in their blood or urine (diabetic ketoacidosis); and in those with severe renal impairment, end stage renal disease, or in patients on dialysis.
Taken from FDA Press Announcements
Northwestern Medicine scientists have demonstrated how metformin, a drug widely used to treat patients with type II diabetes, inhibits cancer progression. Recent studies suggest that the anti–diabetic drug prevents cancer progression, but how metformin diminishes tumor growth is not fully understood. Metformin works by decreasing insulin in the blood. It is postulated that since cancer cells need insulin to multiply, the drug slows down tumor growth by cutting the energy supply produced by their mitochondria. Navdeep S. Chandel, PhD, professor in Medicine–Pulmonary and Cell and Molecular Biology, and collaborators showed that metformin inhibits the function of mitochondrial complex I in human cancer cells, which reduces tumor burden. Mitochondrial complex I is a compound central to energy production in the cell. First authors are William W. Wheaton, graduate student in Walter S. and Lucienne Driskill Graduate Training Program in Life Sciences, and Samuel E. Weinberg, MD/PhD student in the Medical Scientist Training Program. The paper was published May 13 in eLife.
Taken from Northwestern University Feinberg School of Medicine News
Looking for a better pharmacy?
GoodPill Health News
A compilation of the latest news regarding health, foods, medications, recalls, and other pertinent information from different sources.
HOURS OF OPERATION
17177 Pines Boulevard,